<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630017</url>
  </required_header>
  <id_info>
    <org_study_id>207259</org_study_id>
    <nct_id>NCT02630017</nct_id>
  </id_info>
  <brief_title>Motivated Behavior in Adults With and Without ADHD</brief_title>
  <acronym>MOBE</acronym>
  <official_title>Motivated Behavior in Adults With and Without ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effects of methylphenidate on motivated behavior in adults with and
      without ADHD
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in motivated behavior on the bandit task</measure>
    <time_frame>1 hour post drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Drug condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg methylphenidate on one study day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo condition</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo on other study day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate</intervention_name>
    <description>double-blind, counter-balanced administration</description>
    <arm_group_label>Drug condition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>double-blind, counter-balanced administration</description>
    <arm_group_label>Placebo condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. generally healthy

          2. between the ages of 18-45

          3. non-ADHD subjects do not meet criteria for ADHD diagnosis or any subtype as determined
             by the Conners Diagnostic Interview or any T-Score &gt; 55 on Inattentive Symptoms,
             Hyperactive-Impulsive Symptoms, Total Symptoms or ADHD Index subscales of the CAARS.

          4. ADHD subjects meet criteria for a primary diagnosis of ADHD, any subtype, based on
             DSM-5

        Exclusion Criteria:

          1. inability to attend all required experimental sessions

          2. significant health problems (e.g., current and uncontrolled liver, lung, or heart
             problems, current or past seizure disorder, serious head trauma)

          3. primary diagnosis of Axis I psychiatric disorders other than ADHD (e.g., depression,
             anxiety disorder, schizophrenia)

          4. meet DSM-5 criteria for substance use disorder other than nicotine in the past 12
             months

          5. use of psychoactive medications in the past 6 months as indicated by self-report

          6. positive urine drug screen for drugs or positive breath alcohol concentration

          7. contraindications for MPH

          8. among women, nursing or a positive pregnancy test

          9. IQ &lt; 80 on Kaufman Brief Intelligence Test, 2nd edition

         10. allergy to lactose

         11. hypertension (If subject is â‰¤ 40 years of age and has blood pressure over 135/85 or
             heart rate over 90 beats per minute. If subject is &gt; 40 years of age and has blood
             pressure over 130/80 or heart rate over 88 beats per minute)

         12. body mass ratio &gt; 30
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Merideth A Addicott, PhD</last_name>
    <phone>501-526-8436</phone>
    <email>MAddicott@uams.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merideth Addicott, PhD</last_name>
      <phone>501-526-8436</phone>
      <email>MAddicott@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Merideth A Addicott, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

